Spero Therapeutics (STU:2HA) Short Interest


STU:2HA Spero Therapeutics Inc STU:2HA
43 GF Score
Price €1.85
GF Value €0.93
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spero Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:2HA vs ORMP, PLYX, HRTX: Short Interest Comparison

For the Biotechnology subindustry, Spero Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Short Interest falls into.


STU:2HA
43GF Score
Spero Therapeutics Inc STU:2HA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Spero Therapeutics (STU:2HA) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of €1.85 is trading 99.4% above its estimated GF Value™ of €0.93. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:2HA:

  • Short Interest:
  • GF Value™: €0.93 vs. price of €1.85 (99.4% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the STU:2HA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spero Therapeutics Business Description

Other Exchanges SPRO:USA
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
43GF Score

Get the complete analysis for STU:2HA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.85
Price
€0.93
GF Value